Investor Diligence and Decision Support
We support VC/CVC teams, Private Equity, Hedge Funds, and other investors with decision-grade intelligence in BioPharma, HealthTech, and AI-enabled healthcare. From fast diligence to ongoing monitoring, we help you validate assumptions, surface risks early, and act with confidence.
From identifying emerging trends and hidden risks to supporting diligence and portfolio decisions, we deliver concise, actionable recommendations that create an edge.
Our work commonly includes:
- Landscape + diligence (science, commercial, competitive dynamics)
- Company/asset profile (TAM, segmentation, growth drivers, value proposition)
- Opportunity/risk assessment (red flags, catalysts, scenarios, mitigations)
- Custom research aligned to your thesis and timelines (deal-specific questions, thesis validation, monitoring)
Typical engagement modes:
- Diligence Sprint (5–10 business days)
- Monthly monitoring and brief updates
- Decision workshops and AI-powered wargaming when stakes are high
Don’t forget to check out our Lucid Diligence Briefs, delivering 60-second theses, questions to ask, red flags and catalysts to watch, linked to trending news.
Want to move faster on your next decision? Contact: info@lqventures.com
December 26, 2025
Respiratory 2025 Review: From Symptom Control to Disease Modification
December 26, 2025
Vaccines 2025 Review: From Emergency Platforms to Durable Public Health Assets
December 25, 2025
Lucid Diligence Brief: Sanofi moves to buy Dynavax for $2.2B
December 25, 2025
Cell and Gene Therapy 2025 Review: Acceleration, Accountability, and the Fight for Scalability
December 24, 2025
Neuroscience 2025 Review: Disease Modification Meets Deliverability
December 24, 2025
Women’s Health 2025 Review: From Fragmented Care to Scaled Platforms
December 23, 2025
Obesity Review 2025: The Rise of Oralization, the Muscle Question, and a New Era of Access Pressure
December 22, 2025
Lucid Diligence Brief: Jacobio and AstraZeneca pan-KRAS asset deal
December 22, 2025